Treatment of refractory acute nonlymphocytic leukemia with a combination of pyrazofurin and cytarabine

Kaplan, H.G.; Appelbaum, F.R.; Cheever, M.A.; Greenberg, P.D.; Wood, T.; Fefer, A.; Kaplan, H.G; Appelbaum, F.R; Cheever, M.A; Greenberg, P.D; Wood, T; Fefer, A

Home

>

Node

>

Subnode

Treatment of refractory acute nonlymphocytic leukemia with a combination of pyrazofurin and cytarabine

Kaplan, H.G.; Appelbaum, F.R.; Cheever, M.A.; Greenberg, P.D.; Wood, T.; Fefer, A.

Cancer Treatment Reports 66(6): 1397-1398

1982

ISSN/ISBN: 0361-5960

PMID: 7083242

Document Number: 194732

Six patients with refractory acute nonlymphocytic leukemia were treated with pyrazofurin (15 mg/m2) followed by cytarabine (100 mg/m2) every 12 hours for 6--21 days. All patients cleared their peripheral blood of blast cells but no complete remissions were achieved. Excessive toxicity to skin and mucous membranes was observed. In the doses used, this combination is too toxic for further use. Alternate treatment schedules should be explored.